Catalyst

Slingshot members are tracking this event:

Development of Omecamtiv Mecarbil Questionable to Continue to Phase 3 - Decision Expected This Year

Source Link:
http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-newsArticle&ID=2128037

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN
100%
CYTK
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Cytokinetics and Amgen in partnership will continue to develop Omecamtiv mecarbil  for the treatment of heart failure despite it failing its primary efficacy endpoint in the ATOMIC-AHF Phase 2b study in 2013.  A recent study (COSMIC-HF) in 2015 met its primary pharmacokinetics objective, but did not test for efficacy.  Omecamtiv mecarbil is currently being studied on Japanese patients with heart failure, but the primary endpoint observes dose escalation.  
https://www.clinical...
Additional Relevant Details "the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016"
http://www.globenews...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 01, 2016
Occurred Source:
http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-newsArticle&ID=2198921
Related Projects Image
Related Keywords Omecamtiv Mecarbil, Japan, Heart Failure
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.